rilzabrutinib (SAR444671) - Sanofi
Rilzabrutinib: Final data from P2 trial (NCT05104892) for moderate-severe asthma in H1 2024 (Sanofi) - Dec 7, 2023 - R&D Day 
P2 data • Asthma • Immunology
https://www.sanofi.com/assets/dotcom/content-app/events/investor-presentation/2023/r-and-d-day-2023/Presentation.pdf
 
Dec 7, 2023
 
 
74d3cac1-8944-4166-ac4e-d1dfe840e4cb.png